

# Quarraisha Abdool Karim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11176705/publications.pdf>

Version: 2024-02-01

136  
papers

9,969  
citations

71102

41  
h-index

36028

97  
g-index

137  
all docs

137  
docs citations

137  
times ranked

9275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. <i>Science</i> , 2010, 329, 1168-1174.	12.6	2,239
2	Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. <i>New England Journal of Medicine</i> , 2010, 362, 697-706.	27.0	608
3	HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. <i>Lancet, The</i> , 2006, 368, 489-504.	13.7	496
4	Integration of Antiretroviral Therapy with Tuberculosis Treatment. <i>New England Journal of Medicine</i> , 2011, 365, 1492-1501.	27.0	451
5	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. <i>Lancet, The</i> , 2009, 374, 921-933.	13.7	414
6	Adolescent girls and young women: key populations for HIV epidemic control. <i>Journal of the International AIDS Society</i> , 2015, 18, 19408.	3.0	361
7	Genital Inflammation and the Risk of HIV Acquisition in Women. <i>Clinical Infectious Diseases</i> , 2015, 61, 260-269.	5.8	354
8	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. <i>Science</i> , 2017, 356, 938-945.	12.6	348
9	Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. <i>Nature Medicine</i> , 2012, 18, 1688-1692.	30.7	273
10	Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. <i>Lancet, The</i> , 2011, 378, 279-281.	13.7	220
11	Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. <i>Lancet HIV,the</i> , 2017, 4, e41-e50.	4.7	220
12	Achieving the health Millennium Development Goals for South Africa: challenges and priorities. <i>Lancet, The</i> , 2009, 374, 1023-1031.	13.7	214
13	Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. <i>Aids</i> , 2010, 24, 819-831.	2.2	195
14	Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study. <i>PLoS ONE</i> , 2008, 3, e1954.	2.5	175
15	Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. <i>Sexually Transmitted Infections</i> , 2014, 90, 580-587.	1.9	173
16	Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. <i>PLoS Medicine</i> , 2015, 12, e1001778.	8.4	170
17	Innate Immune Activation Enhances HIV Acquisition in Women, Diminishing the Effectiveness of Tenofovir Microbicide Gel. <i>Journal of Infectious Diseases</i> , 2012, 206, 993-1001.	4.0	137
18	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. <i>Nature Medicine</i> , 2018, 24, 491-496.	30.7	123

#	ARTICLE	IF	CITATIONS
19	Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. <i>International Journal of Epidemiology</i> , 2011, 40, 922-930.	1.9	109
20	Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 209, 500-509.	4.0	99
21	Seroprevalence of HIV infection in rural South Africa. <i>Aids</i> , 1992, 6, 1535-1540.	2.2	93
22	Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire. <i>Journal of Immunology</i> , 2015, 194, 4371-4378.	0.8	85
23	Integrin $\alpha 4 \beta 7$ expression on peripheral blood CD4 <sup>+</sup> T cells predicts HIV acquisition and disease progression outcomes. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	85
24	Antiretroviral prophylaxis: a defining moment in HIV control. <i>Lancet</i> , The, 2011, 378, e23-e25.	13.7	84
25	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016, 12, e1005742.	4.7	81
26	Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 530-539.	27.0	80
27	Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S17-S26.	2.1	80
28	Relationship between Levels of Inflammatory Cytokines in the Genital Tract and CD4 <sup>+</sup> Cell Counts in Women with Acute HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2008, 198, 710-714.	4.0	71
29	Genital Tract Inflammation During Early HIV-1 Infection Predicts Higher Plasma Viral Load Set Point in Women. <i>Journal of Infectious Diseases</i> , 2012, 205, 194-203.	4.0	67
30	Genital Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 318-325.	2.1	64
31	Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey. <i>Lancet HIV</i> , the, 2018, 5, e427-e437.	4.7	60
32	The evolving HIV epidemic in South Africa. <i>International Journal of Epidemiology</i> , 2002, 31, 37-40.	1.9	54
33	HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their Inclusion in HIV Biomedical Intervention Trials. <i>AIDS and Behavior</i> , 2012, 16, 1870-1876.	2.7	54
34	Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. <i>Clinical Infectious Diseases</i> , 2017, 64, 79-82.	5.8	53
35	Epidemiological Impact of Tenofovir Gel on the HIV Epidemic in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 207-210.	2.1	51
36	Trends in HIV Prevalence in Pregnant Women in Rural South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 289-295.	2.1	51

#	ARTICLE	IF	CITATIONS
37	Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection. <i>Sexually Transmitted Infections</i> , 2016, 92, 186-193.	1.9	50
38	Acceptability of HIV self-testing among men and women in KwaZulu-Natal, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 186-192.	1.2	50
39	Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection. <i>PLoS ONE</i> , 2013, 8, e53251.	2.5	49
40	Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. <i>Sexually Transmitted Infections</i> , 2014, 90, 620-626.	1.9	47
41	Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial. <i>AIDS and Behavior</i> , 2014, 18, 849-854.	2.7	44
42	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. <i>Nature Communications</i> , 2019, 10, 5227.	12.8	40
43	Factors Driving the HIV Epidemic in Southern Africa. <i>Current HIV/AIDS Reports</i> , 2016, 13, 158-169.	3.1	38
44	Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 212, 754-759.	4.0	36
45	Uptake of provider-initiated HIV testing and counseling among women attending an urban sexually transmitted disease clinic in South Africa – missed opportunities for early diagnosis of HIV infection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 533-537.	1.2	35
46	Implementing antiretroviral therapy in resource-constrained settings. <i>Aids</i> , 2004, 18, 975-979.	2.2	33
47	Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. <i>Trials</i> , 2011, 12, 67.	1.6	33
48	Development of Methods for Cross-Sectional HIV Incidence Estimation in a Large, Community Randomized Trial. <i>PLoS ONE</i> , 2013, 8, e78818.	2.5	33
49	Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. <i>BMC Public Health</i> , 2015, 15, 1149.	2.9	33
50	Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa. <i>JAMA Network Open</i> , 2019, 2, e1914378.	5.9	33
51	Contraceptive Choices, Pregnancy Rates, and Outcomes in a Microbicide Trial. <i>Obstetrics and Gynecology</i> , 2011, 118, 895-904.	2.4	32
52	Co-enrollment in multiple HIV prevention trials – Experiences from the CAPRISA 004 Tenofovir gel trial. <i>Contemporary Clinical Trials</i> , 2011, 32, 333-338.	1.8	27
53	Metabolic Syndrome After HIV Acquisition in South African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 438-445.	2.1	26
54	Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. <i>Journal of the International AIDS Society</i> , 2018, 21, e25082.	3.0	26

#	ARTICLE	IF	CITATIONS
55	Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis. <i>Frontiers in Immunology</i> , 2021, 12, 730986.	4.8	25
56	Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype. <i>Journal of Immunology</i> , 2015, 195, 2273-2281.	0.8	24
57	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. <i>Cell Host and Microbe</i> , 2018, 24, 593-599.e3.	11.0	24
58	HIV Infection in High School Students in Rural South Africa: Role of Transmissions Among Students. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 956-965.	1.1	23
59	Acceptability of Early Antiretroviral Therapy Among South African Women. <i>AIDS and Behavior</i> , 2018, 22, 1018-1024.	2.7	22
60	Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression. <i>Clinical Immunology</i> , 2018, 195, 127-138.	3.2	22
61	Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial. <i>Antiviral Therapy</i> , 2013, 18, 301-310.	1.0	21
62	Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial. <i>AIDS and Behavior</i> , 2014, 18, 811-819.	2.7	21
63	The HIV Epidemic in Southern Africa – Is an AIDS-Free Generation Possible?. <i>Current HIV/AIDS Reports</i> , 2014, 11, 99-108.	3.1	21
64	Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. <i>AIDS and Behavior</i> , 2014, 18, 841-848.	2.7	20
65	Preservation HIV-1-Specific IFN $\gamma$ + CD4+ T-Cell Responses in Breakthrough Infections After Exposure to Tenofovir Gel in the CAPRISA 004 Microbicide Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 124-127.	2.1	19
66	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on $\beta$ 4 $\beta$ 7 for replication. <i>Retrovirology</i> , 2015, 12, 54.	2.0	19
67	Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. <i>Aids</i> , 2016, 30, 1005-1014.	2.2	18
68	Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa. <i>Culture, Health and Sexuality</i> , 2017, 19, 1268-1285.	1.8	18
69	Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women. <i>Journal of Immunology</i> , 2017, 198, 1220-1228.	0.8	18
70	CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women. <i>BMJ Open</i> , 2022, 12, e052880.	1.9	18
71	Topical Microbicides – What's New?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S144-S149.	2.1	17
72	Initiating antiretrovirals during tuberculosis treatment: a drug safety review. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 559-574.	2.4	16

#	ARTICLE	IF	CITATIONS
73	CAPRISA 004 Tenofovir Microbicide Trial: No Impact of Tenofovir Gel on the HIV Transmission Bottleneck. <i>Journal of Infectious Diseases</i> , 2012, 206, 35-40.	4.0	16
74	Plasma concentration of injectable contraceptive correlates with reduced cervicovaginal growth factor expression in South African women. <i>Mucosal Immunology</i> , 2020, 13, 449-459.	6.0	15
75	HIV-Associated Tuberculosis. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	14
76	Experience in international clinical research: the HIV Prevention Trials Network. <i>Clinical Investigation</i> , 2011, 1, 1609-1618.	0.0	14
77	Natural killer cell function in women at high risk for HIV acquisition. <i>Aids</i> , 2012, 26, 1745-1753.	2.2	14
78	Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1521-1525.	1.2	14
79	Limited HIV-1 Superinfection in Seroconverters from the CAPRISA 004 Microbicide Trial. <i>Journal of Clinical Microbiology</i> , 2014, 52, 844-848.	3.9	14
80	High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 438-446.	2.1	14
81	Inclusion of adolescent girls in HIV prevention research – an imperative for an AIDS-free generation. <i>Journal of the International AIDS Society</i> , 2014, 17, 19075.	3.0	13
82	Sensitive Tenofovir Resistance Screening of HIV-1 From the Genital and Blood Compartments of Women With Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 1916-1920.	4.0	13
83	Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression. <i>Journal of Virology</i> , 2017, 91, .	3.4	13
84	Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. <i>Aids</i> , 2017, 31, 2199-2209.	2.2	13
85	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2019, 22, e25381.	3.0	13
86	Empowering women in human immunodeficiency virus prevention. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 487-493.	2.8	12
87	Social Context of Adherence in an Open-Label 1% Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa. <i>AIDS and Behavior</i> , 2016, 20, 2682-2691.	2.7	12
88	Development of a prognostic tool exploring female adolescent risk for HIV prevention and PrEP in rural South Africa, a generalised epidemic setting. <i>Sexually Transmitted Infections</i> , 2020, 96, 47-54.	1.9	12
89	Utilizing nucleic acid amplification to identify acute HIV infection. <i>Aids</i> , 2007, 21, 653-655.	2.2	11
90	Microbicides for the prevention of sexually transmitted HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 12-23.	4.4	11

#	ARTICLE	IF	CITATIONS
91	No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial. PLoS ONE, 2013, 8, e71758.	2.5	11
92	The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. South African Medical Journal, 2010, 100, 808.	0.6	10
93	Monitoring Microbicide Gel Use with Real-Time Notification of the Container's Opening Events: Results of the CAPRISA Wisebag Study. AIDS and Behavior, 2014, 18, 833-840.	2.7	10
94	Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial. PLoS ONE, 2013, 8, e56400.	2.5	9
95	Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials, 2014, 15, 496.	1.6	9
96	Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case-Control Study. AIDS and Behavior, 2014, 18, 826-832.	2.7	9
97	Antibodies for HIV prevention in young women. Current Opinion in HIV and AIDS, 2015, 10, 183-189.	3.8	9
98	Putting women in the centre of the global HIV response is key to achieving epidemic control!. Journal of the International AIDS Society, 2020, 23, e25473.	3.0	9
99	Antiretroviral prophylaxis for HIV prevention reaches a key milestone. Lancet, The, 2012, 379, 2047-2048.	13.7	8
100	Implementing microbicides in low-income countries. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 495-501.	2.8	8
101	The Preventive Misconception: Experiences from CAPRISA 004. AIDS and Behavior, 2014, 18, 1746-1752.	2.7	8
102	Measuring Adherence by Visual Inspection of Returned Empty Gel Applicators in the CAPRISA 004 Microbicide Trial. AIDS and Behavior, 2014, 18, 820-825.	2.7	7
103	Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa. Scientific Reports, 2020, 10, 13017.	3.3	7
104	Current status of the HIV epidemic & challenges in prevention. Indian Journal of Medical Research, 2017, 146, 673.	1.0	7
105	Neither Microbial Translocation Nor TLR Responsiveness Are Likely Explanations for Preexisting Immune Activation in Women Who Subsequently Acquired HIV in CAPRISA 004. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 294-298.	2.1	6
106	Anti-retrovirals for treatment and prevention - time for new paradigms in our response to the HIV/AIDS epidemic?. Developing World Bioethics, 2013, 13, ii-iii.	0.9	6
107	Challenges with participant reimbursement: experiences from a post-trial access study. Journal of Medical Ethics, 2015, 41, 909-913.	1.8	6
108	Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 734-740.	1.2	6

#	ARTICLE	IF	CITATIONS
109	Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression. Scientific Reports, 2022, 12, 2437.	3.3	6
110	Antiretroviral therapy: challenges and options in South Africa. Lancet, The, 2003, 362, 1499.	13.7	5
111	Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 43-47.	2.1	5
112	Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women. PLoS ONE, 2018, 13, e0200359.	2.5	5
113	Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection. Journal of the International AIDS Society, 2021, 24, e25766.	3.0	5
114	The Impact of Semen Exposure on the Immune and Microbial Environments of the Female Genital Tract. Frontiers in Reproductive Health, 2020, 2, .	1.9	4
115	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. Clinical Infectious Diseases, 2021, 73, 1528-1531.	5.8	4
116	Exploratory analysis of the ecological variables associated with sexual health profiles in high-risk, sexually-active female learners in rural KwaZulu-Natal. PLoS ONE, 2018, 13, e0195107.	2.5	3
117	Who is sexually active? Using a multi-component sexual activity profile (MSAP) to explore, identify and describe sexually-active high-school students in rural KwaZulu-Natal, South Africa. BMC Public Health, 2019, 19, 317.	2.9	3
118	Higher mucosal antibody concentrations in women with genital tract inflammation. Scientific Reports, 2021, 11, 23514.	3.3	3
119	Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial. Antiviral Research, 2013, 99, 405-408.	4.1	2
120	Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials. Antiviral Therapy, 2016, 22, 287-293.	1.0	2
121	Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women. Aids, 2017, 31, 191-197.	2.2	2
122	Closing the NIH Fogarty Center threatens US and global health. Lancet, The, 2017, 390, 451.	13.7	2
123	<i>â€œYouâ€™ll always stay rightâ€™</i> understanding vaginal products and the motivations for use among adolescent and young women in rural KZN. Culture, Health and Sexuality, 2019, 21, 95-107.	1.8	2
124	Engaging young women in Africa for PrEP use and adherence. Lancet HIV,the, 2021, 8, e122-e123.	4.7	2
125	Genital immune cell activation and tenofovir gel efficacy: a case-control study. Clinical Infectious Diseases, 2022, , .	5.8	2
126	Tenofovir Gel to Prevent HSV-2 Infection. New England Journal of Medicine, 2015, 373, 1980-1981.	27.0	1



#	ARTICLE	IF	CITATIONS
127	Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women. <i>Frontiers in Immunology</i> , 2020, 11, 1274.	4.8	1
128	Genital and systemic immune effects of the injectable, contraceptive norethisterone enanthate (NET-EN), in South African women. <i>American Journal of Reproductive Immunology</i> , 2021, 86, e13411.	1.2	1
129	Commentary title: COVID-19 research, Africa, and global health. <i>Journal of Virus Eradication</i> , 2021, 7, 100030.	0.5	1
130	Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	1.0	1
131	Case 15-2011. <i>New England Journal of Medicine</i> , 2011, 364, 1956-1964.	27.0	0
132	Exploring discrepant knowledge of partner sexual behaviour to inform self-risk assessment in a high HIV burdened district in rural KwaZulu-Natal. <i>Global Public Health</i> , 2021, , 1-16.	2.0	0
133	Prevention Clinical Trials: Highlights of Evidence and Research. , 2017, , 1-11.		0
134	Antiretrovirals for HIV Prevention: The CAPRISA 004 Tenofovir Gel Trial. , 2017, , 41-56.		0
135	Prevention Clinical Trials: Highlights of Evidence and Research. , 2018, , 1713-1723.		0
136	Age-Restriction of a Validated Risk Scoring Tool Better Predicts HIV Acquisition in South African Women: CAPRISA 004. <i>AIDS and Behavior</i> , 2022, , 1.	2.7	0